Targeting CDK9 for treatment of colorectal cancer

Colorectal cancer (CRC) remains one of the most lethal human malignancies, and pursuit of new therapeutic targets for treatment has been a major research focus. Cyclin‐dependent kinase 9 (CDK9), which plays a crucial role in transcription, has emerged as a target for cancer treatment. CDKI‐73, one of the most potent and pharmacologically superior CDK9 inhibitors, has demonstrated excellent anti‐tumour efficacy against several types of cancers. In this study, we evaluated its therapeutic potential against CRC. CDKI‐73 elicited high cytotoxicity against all colon cancer cell lines tested. Cell cycle and apoptosis analysis in HCT 116 and HT29 cells revealed that CDKI‐73 induced cell death without accumulation of DNA at any phase of the cell cycle. Moreover, it caused depolarisation of mitochondrial membrane, leading to caspase‐independent apoptosis. Knockdown by shRNA demonstrated the CDK9‐targeted mechanism of CDKI‐73, which also affected the Mnk/eIF4E signalling axis. In addition, RT‐qPCR analysis showed that CDKI‐73 down‐regulated multiple pro‐survival factors at the mRNA level. Its in vivo anti‐tumour efficacy was further evaluated in Balb/c nude mice bearing HCT 116 xenograft tumours. CDKI‐73 significantly inhibited tumour growth (***P < 0.001) without overt toxicity. Analysis of the tumour tissues collected from the xenografted animals confirmed that the in vivo anti‐tumour efficacy was associated with CDK9 targeting of CDKI‐73. Overall, this study provides compelling evidence that CDKI‐73 is a promising drug candidate for treating colorectal cancer.

[1]  W. Kerwin,et al.  Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition , 2017, Scientific Reports.

[2]  Shudong Wang,et al.  Targeting CDK9: a promising therapeutic opportunity in prostate cancer. , 2016, Endocrine-related cancer.

[3]  A. V. van Kessel,et al.  The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery , 2016, Cellular Oncology.

[4]  L. Kats,et al.  The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. , 2016, Cancer research.

[5]  A. Giordano,et al.  Overview of CDK9 as a target in cancer research , 2016, Cell cycle.

[6]  I. Lewis,et al.  Investigation of a Novel Cyclin-Dependent-Kinase (CDK) Inhibitor Cdki-73 As an Effective Treatment Option for MLL-AML , 2015 .

[7]  D. Arango,et al.  Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment , 2015, Clinical Cancer Research.

[8]  M. Grever,et al.  Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. , 2015, Leukemia research.

[9]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[10]  H. Hirsch,et al.  MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis , 2014, PloS one.

[11]  Darjus F. Tschaharganeh,et al.  CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma , 2014, Genes & development.

[12]  Yi Chen,et al.  Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73 , 2014, Oncotarget.

[13]  C. Proud,et al.  MAP kinase-interacting kinases--emerging targets against cancer. , 2014, Chemistry & biology.

[14]  C. Midgley,et al.  Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities. , 2014, Journal of Medicinal Chemistry.

[15]  A. Jemal,et al.  Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[16]  C. Fegan,et al.  A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine , 2013, Oncotarget.

[17]  R. Lothe,et al.  Epigenetic and genetic features of 24 colon cancer cell lines , 2013, Oncogenesis.

[18]  E. Sausville,et al.  Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias , 2013, Cancer Chemotherapy and Pharmacology.

[19]  P. Hoffmann,et al.  Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis , 2013, Oncotarget.

[20]  S. Grant,et al.  Cyclin-dependent kinase inhibitor therapy for hematologic malignancies , 2013, Expert opinion on investigational drugs.

[21]  S. Tait,et al.  Multiple functions of BCL-2 family proteins. , 2013, Cold Spring Harbor perspectives in biology.

[22]  M. Noble,et al.  Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities , 2013, Journal of Medicinal Chemistry.

[23]  R. Rustandi,et al.  Qualitative and quantitative evaluation of Simon™, a new CE‐based automated Western blot system as applied to vaccine development , 2012, Electrophoresis.

[24]  S. Baumli,et al.  Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target , 2012, Current pharmaceutical design.

[25]  Daniel P. Stewart,et al.  Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration , 2012, Nature Cell Biology.

[26]  B. Hadaschik,et al.  Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker , 2012, BMC Cancer.

[27]  P. Fischer,et al.  CDKI‐71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol , 2012, International journal of cancer.

[28]  C. Proud,et al.  Targeting Mnks for Cancer Therapy , 2012, Oncotarget.

[29]  C. Ricciardelli,et al.  The ADAMTS1 protease gene is required for mammary tumor growth and metastasis. , 2011, The American journal of pathology.

[30]  A. Montagnoli,et al.  Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells , 2011, Molecular Cancer Therapeutics.

[31]  Peter M Fischer,et al.  Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. , 2010, Chemistry & biology.

[32]  E. Lees,et al.  Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor , 2010, Molecular Cancer Therapeutics.

[33]  A. Bardelli,et al.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Garnier,et al.  Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. , 2008, Cardiovascular research.

[35]  Peter M Fischer,et al.  Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. , 2008, Trends in pharmacological sciences.

[36]  Thomas S. Lin,et al.  Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. , 2008, Blood.

[37]  S. Ryser,et al.  Up-Regulation of P-TEFb by the MEK1-Extracellular Signal-Regulated Kinase Signaling Pathway Contributes to Stimulated Transcription Elongation of Immediate Early Genes in Neuroendocrine Cells , 2007, Molecular and Cellular Biology.

[38]  Daniel Alex Finkelstein,et al.  Spotlight , 2007 .

[39]  Anping Li,et al.  Cyclin D1 Determines Mitochondrial Function InVivo , 2006, Molecular and Cellular Biology.

[40]  Gudrun Tellmann,et al.  The E-Method: a highly accurate technique for gene-expression analysis , 2006 .

[41]  M. Grever,et al.  Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. , 2005, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[42]  W. Plunkett,et al.  Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. , 2005, Blood.

[43]  G. Gores,et al.  The Anti-apoptotic Protein Mcl-1 Inhibits Mitochondrial Ca2+ Signals* , 2005, Journal of Biological Chemistry.

[44]  David Loegering,et al.  Components of the Cell Death Machine and Drug Sensitivity of the National Cancer Institute Cell Line Panel , 2004, Clinical Cancer Research.

[45]  W. Craigen,et al.  Activation of cardiac Cdk9 represses PGC‐1 and confers a predisposition to heart failure , 2004, The EMBO journal.

[46]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[47]  A. Osnowski,et al.  2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. , 2004, Journal of medicinal chemistry.

[48]  E. Vokes,et al.  Phase II study of flavopiridol in patients with advanced colorectal cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  I. Gojo,et al.  The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  Andreas Rosenwald,et al.  Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol , 2001, Genome Biology.

[51]  G. Scheper,et al.  The Mitogen-Activated Protein Kinase Signal-Integrating Kinase Mnk2 Is a Eukaryotic Initiation Factor 4E Kinase with High Levels of Basal Activity in Mammalian Cells , 2001, Molecular and Cellular Biology.

[52]  C. Thompson,et al.  The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability , 2000, Cell Death and Differentiation.

[53]  C. Horvath,et al.  Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate. , 2000, Cancer research.

[54]  Jonathan A. Cooper,et al.  Mitogen‐activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2 , 1997, The EMBO journal.

[55]  M. Noble,et al.  Substituted 4-(Thiazol-5-Yl)-2-(Phenylamino)Pyrimidines are Highly Active Cdk9 Inhibitors: Synthesis, X-Ray Crystal Structure, Sar and Anti-Cancer Activities. , 2013 .

[56]  Lorenzo Galluzzi,et al.  Mitochondrial membrane permeabilization in cell death. , 2007, Physiological reviews.

[57]  C. Oshima,et al.  Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. , 2005, Neoplasma.

[58]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.

[59]  P. Brandtzaeg,et al.  Clinical and laboratory studies , 1986 .